comparemela.com

Latest Breaking News On - Recro pharma inc - Page 6 : comparemela.com

Roth Capital

Marchex, Inc. (NASDAQ: MCHX) has been undergoing a period of transformation and should become a growth business in 2019 and beyond, according to Roth Capital. The Analyst Roth Capital’s Darren Aftahi upgraded Marchex from Neutral to Buy and raised the price target from $3.40 to $7. The Thesis. Read More.

Recro Strengthens Business Development Team to Drive Customer Growth and Diversification

Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Opioid | Benzinga

October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500 s 7 percent retreat. As we enter the last leg of the year, here are a few PDUFA. Read More.

Mid-Day Market Update: Nasdaq Rises Over 100 Points; Recro Pharma Shares Plummet

Mid-Day Market Update: Nasdaq Rises Over 100 Points; Recro Pharma Shares Plummet
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.